Evidence map›Paper›PMID 42440300›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026

Gut-Derived Sodium Butyrate Attenuates Liver Fibrosis by Inhibiting Aerobic Glycolysis via the HDAC3/c-Myc Signaling Axis.

Yong Sun, Huayue Wu, Yutong Zhou, Pengsheng Yin, Long Wu, Haiyang Li, Shi Zuo, Zhe Yang, Kun Cao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yong SunSchool of Clinical Medicine, Guizhou Medical University, Guiyang, Guizhou, China.ORCID https://orcid.org/0009-0009-1600-857X
Huayue WuSchool of Clinical Medicine, Guizhou Medical University, Guiyang, Guizhou, China.
Yutong ZhouSchool of Clinical Medicine, Guizhou Medical University, Guiyang, Guizhou, China.
Pengsheng YinSchool of Clinical Medicine, Guizhou Medical University, Guiyang, Guizhou, China.
Long WuSchool of Clinical Medicine, Guizhou Medical University, Guiyang, Guizhou, China.
Haiyang LiSchool of Clinical Medicine, Guizhou Medical University, Guiyang, Guizhou, China.
Shi ZuoSchool of Clinical Medicine, Guizhou Medical University, Guiyang, Guizhou, China.
Zhe YangSchool of Basic Medicine, Guizhou Medical University, Guiyang, Guizhou, China.
Kun CaoSchool of Clinical Medicine, Guizhou Medical University, Guiyang, Guizhou, China.

Funding

Basic Research Program (General Project) of the Guizhou Provincial Department of Science and Technology MS(2026)576Guizhou Provincial Key Laboratory for Digestive System Diseases ZSYS(2025)021National Natural Science Foundation of China 82560134Project of Key Laboratory of Diagnosis and Treatment of Hepatobiliary and Pancreatic Diseases and Bioinformatics Research, Guizhou Medical University 2024FY-001Technology Foundation of Guizhou Health Committee gzwkj2024-136Youth-Guided Basic Research Program of the Guizhou Provincial Department of Science and Technology QN[2025]416
6 · The paper itself

Abstract

Liver fibrosis remains a major global health challenge, driving interest in bioactive metabolites from natural sources as potential therapies. Sodium butyrate (NaB), a gut microbiota-derived short-chain fatty acid with notable anti-fibrotic activity, shows promise, although its mechanisms remain unclear. This study aims to explore the molecular mechanisms through which NaB attenuates liver fibrosis. This study integrates bioinformatics and network pharmacology to predict the molecular targets through which NaB exerts its anti-fibrotic effects. Candidate targets were validated through molecular docking, histopathology, CETSA, and SPR. The inferred mechanisms were further validated in vitro (LX-2 cells) and in vivo (CCl

Indexed as

Butyric AcidGlycolysisHistone DeacetylasesLiver CirrhosisProto-Oncogene Proteins c-mycSignal TransductionAnimalsCell LineHepatic Stellate CellsHistone Deacetylase 3HumansMaleMiceMice, Inbred C57BLButyric AcidHistone Deacetylase 3Histone DeacetylasesProto-Oncogene Proteins c-mycglycolysishepatic stellate cellshistone deacetylasesliver fibrosissodium butyrate

Identifiers

PMID42440300
PMCPMC13361148

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.